Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics unit. The company closed a deal with Johnson & Johnson (NYSE:JNJ) on Wednesday to manufacture the pharma’s COVID-19 vaccine (see “J&J’s Second Manufacturing Partner”).

Dana-Farber Cancer Institute and Harvard Medical School professor Nathanael Gray will move to Stanford University’s Chemistry, Engineering and Medicine for Human Health (ChEM-H) institute. Gray leads Dana-Farber’s Center for Protein Degradation with Eric Fischer; he also co-founded C4 Therapeutics Inc., Syros Pharmaceuticals Inc. (NASDAQ:SYRS) and Petra Pharma Corp...